Adults 18 to 99, any sex, with Hearing Loss. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Oxygenation Using Functional Near Infrared Spectroscopy (fNIRS)Primary· Session 1, 2, 3 and 4; assessed for up to 2 hours
Infrared light scattered from the prefrontal cortex, which is indicative of concentration of oxygenated blood in that region. fNIRS in the prefrontal cortex is intended to index both motivation and listening effort.
Hearing aid with noise management
Group
Value
95% CI
Participants With Hearing Loss
-14.85
± 4.65
Hearing aids for quiet listening
Group
Value
95% CI
Participants With Hearing Loss
4.15
± 4.65
Listening AccuracySecondary· Session 1, 2, 3 and 4; assessed for up to 2 hours
Speech understanding in noise percent correct scores
Hearing aids with noise management
Group
Value
95% CI
Participants With Hearing Loss
75.8
± 15.2
Hearing aids for quiet listening
Group
Value
95% CI
Participants With Hearing Loss
62.3
± 19.4
Subjective Listening Effort RatingSecondary· Session 1, 2, 3 and 4; assessed for up to 2 hours
Participants rate how much listening effort was required in order to make out a sentence from 1-7, where lower scores mean less effort required.
Hearing aids with noise management
Group
Value
95% CI
Participants With Hearing Loss
3.08
± 0.960
Hearing aids for quiet listening
Group
Value
95% CI
Participants With Hearing Loss
4.08
± 0.892
Sponsor's own description
The purpose of the current study is to measure oxygenation in the PFC using fNIRS in a sample of older adults with hearing loss. Participants will be instructed to listen to sentences in noise at a challenging signal-to-noise-ratio, and to repeat the word that they heard and rate how much subjective listening effort was required in order to make out the words. fNIRS will be measured throughout. Participants will complete the task using a hearing aid program intended for listening in quiet, and a hearing aid program with new advanced noise management features.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT07176936 — Improving Speech in Noise Using Noninvasive Stimulation
· NA
· recruiting
NCT07506408 — Randomised Study of Web-Based Auditory Training With Varying Perceptual and Cognitive Demands on Training Gains and Gene
· NA
· recruiting
NCT07218913 — Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III
· Phase 1
· recruiting
NCT07414329 — Efficacy and Effectiveness of an Investigational Behind-the-Ear Hearing Device Kit
· NA
· recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms
· NA
· recruiting
Other Sonova AG trials
Trials by the same sponsor.
NCT07526428 — Investigating the DNN Noise Reduction Feature in Phonak Hearing Aids Using Ecological Momentary Assessment
· NA
· enrolling by invitation
NCT07501312 — Remote Microphone Performance Comparison in Adults With Hearing Loss
· NA
· enrolling by invitation
NCT07414329 — Efficacy and Effectiveness of an Investigational Behind-the-Ear Hearing Device Kit
· NA
· recruiting
NCT06957730 — A Comparison of Hearing Aid Noise Programs on Speech Intelligibility
· NA
· completed
NCT06746038 — Evaluation of Extended Wear Hearing Aid for Mild Hearing Loss
· NA
· not yet recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sonova AG
Last refreshed: 17 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05893992.